Your session is about to expire
← Back to Search
TSEP + Rhizotomy for Trigeminal Neuralgia
Phase < 1
Recruiting
Led By David P Darrow, MD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Scheduled to undergo percutaneous rhizotomy for facial pain
Be older than 18 years old
Must not have
For Healthy control: History of any functional pain disorder: fibromyalgia, IBS, CRPS
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group
Summary
This trial looks at if it's possible to use a nerve test to measure pain related to Trigeminal Neuralgia (TGN), a debilitating face pain syndrome.
Who is the study for?
This trial is for adults over 18 who are scheduled for rhizotomy surgery to treat severe facial pain known as trigeminal neuralgia. It's not suitable for individuals with a history of migraines, functional pain disorders like fibromyalgia or IBS, recent chronic pain, unclear facial pain origins, or those whose procedure is canceled.
What is being tested?
The study tests if measuring brain responses (TSEPs) during rhizotomy surgery can help in treating trigeminal neuralgia. Participants will either have TSEP measurements taken alongside their surgery or just the standard surgical procedure without TSEP recording.
What are the potential side effects?
Since this trial involves a surgical procedure (rhizotomy), potential side effects may include discomfort at the stimulation site on the face, infection risk from surgery, and typical post-surgical issues such as swelling or bruising.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for a procedure to treat facial pain.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a history of conditions like fibromyalgia, IBS, or CRPS.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Feasibility
Secondary study objectives
TSEPS latency between control and TGN patients
TSEPS latency within TGN
TSEPS peak to peak amplitude between control and TGN patients
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: TGN patientsExperimental Treatment1 Intervention
Patients with TGN who will undergo rhizotomy surgery as the standard of care
Group II: Healthy volunteersActive Control1 Intervention
Healthy volunteers for whom TSEPS will be recorded in a lab setting
Find a Location
Who is running the clinical trial?
University of MinnesotaLead Sponsor
1,439 Previous Clinical Trials
1,621,928 Total Patients Enrolled
2 Trials studying Trigeminal Neuralgia
35 Patients Enrolled for Trigeminal Neuralgia
David P Darrow, MDPrincipal InvestigatorUniversity of Minnesota
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have never had facial pain like TMD or TGN.I have facial pain that hasn't been diagnosed as trigeminal neuralgia, or my rhizotomy was canceled.I have experienced chronic pain in the last month.I have a history of migraine.I am 18 years old or older.I have a history of conditions like fibromyalgia, IBS, or CRPS.I am scheduled for a procedure to treat facial pain.
Research Study Groups:
This trial has the following groups:- Group 1: TGN patients
- Group 2: Healthy volunteers
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.